ASSESSMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA): RESULTS FROM REGENERATE PHASE 3 CLINICAL TRIAL

被引：0

作者：

Younossi, Zobair M. ^{[1
,2
,3
]}

Stepanova, Maria ^{[4
]}

Nader, Fatema ^{[4
]}

Loomba, Rohit ^{[5
]}

Anstee, Quentin M. ^{[6
]}

Ratziu, Vlad ^{[7
]}

Harrison, Stephen A. ^{[8
]}

Sanyal, Arun J. ^{[9
]}

Trotter, James F. ^{[10
]}

Sheikh, Muhammad Y. ^{[11
]}

Montano-Loza, Aldo J. ^{[12
]}

Olveria, Antonio ^{[13
]}

Stinton, Laura M. ^{[14
]}

Sheridan, David A. ^{[15
,16
]}

Vargas, Victor ^{[17
]}

Gluud, Lise L. ^{[18
]}

Safadi, Rifaat ^{[19
]}

Schattenberg, Joern ^{[20
]}

Khalili, Mandana ^{[21
]}

Orr, David W. ^{[22
]}

Peck-Radosavljevic, Markus ^{[23
]}

Allison, Michael E. ^{[24
]}

Cawkwell, Gail ^{[25
]}

Wong, Bruce ^{[25
]}

Bedossa, Pierre ^{[26
]}

Goodman, Zachary D. ^{[1
,27
]}

Rinella, Mary E. ^{[28
]}

机构：

[1] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA

[2] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA

[3] Inova Fairfax Hosp, Dept Med, Falls Church, VA USA

[4] Ctr Outcomes Res Liver Dis, Washington, DC USA

[5] Univ Calif San Diego, NAFLD Res Ctr, San Diego, CA 92103 USA

[6] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England

[7] AP HP, Paris, France

[8] Univ Oxford, Oxford, England

[9] VCU, Richmond, VA USA

[10] Texas Digest Dis Consultants, Clin Res, Dallas, TX USA

[11] Fresno Clin Res Ctr, Fresno, CA USA

[12] Univ Alberta, Edmonton, AB, Canada

[13] Hosp Univ, Madrid, Spain

[14] Univ Calgary, Med, Calgary, AB, Canada

[15] Plymouth Hosp NHS Trust, Plymouth, Devon, England

[16] Plymouth Univ, Plymouth, Devon, England

[17] Hosp Valle De Hebron, Barcelona, Spain

[18] Copenhagen Univ Hosp Hvidore, Hvidovre, Denmark

[19] Hadassah Hebrew Univ Med Ctr, Hadassah Med Org, Jerusalem, Israel

[20] Univ Med Ctr Mainz, Dept Med, Mainz, Germany

[21] Univ Calif San Francisco, San Francisco, CA 94143 USA

[22] Auckland City Hosp, Auckland, New Zealand

[23] Med Univ Wien, Vienna, Austria

[24] Addenbrookes Hosp, Dept Hepatol, Cambridge, England

[25] Intercept Pharmaceut, New York, NY USA

[26] Hop Beaujon, Clichy, France

[27] Inova Fairfax Hosp, Falls Church, VA USA

[28] Feinberg Sch Med, Chicago, IL USA

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

2324

引用

页码：1366A / 1368A

页数：3

共 50 条

[31] IMPROVED PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH ABATACEPT: RESULTS FROM A PHASE III TRIAL
Strand, V.
Alemao, E.
Lehman, T.
Johnsen, A.
Banerjee, S.
Ahmad, H.
Mease, P.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 687 - 687
[32] Improved Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Abatacept: Results from a Phase III Trial
Strand, Vibeke
Alemao, E.
Lehman, T.
Johnsen, A.
Banerjee, S.
Ahmad, H. A.
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[33] Incidence and median times to onset and resolution of pruritus adverse events in a phase 3 study of obeticholic acid in patients with non-alcoholic steatohepatitis
Younossi, Zobair
Feinman, Leighland
Randhawa, Amarita
Leyva, Rina
Stepanova, Maria
Sawhney, Sangeeta
JOURNAL OF HEPATOLOGY, 2023, 78 : S823 - S823
[34] Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebocontrolled phase 3 trial (vol 394, pg 2184, 2019)
Younossi, Z. M.
Ratziu, V
Loomba, R.
LANCET, 2021, 397 (10292): : 2336 - 2336
[35] Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis
Harrison, Stephen A.
Chalasani, Naga P.
Lawitz, Eric
Marri, Smitha
Noureddin, Mazen
Sanyal, Arun J.
Schiano, Thomas D.
Siddiqui, Mohammad S.
Neuschwander-Tetri, Brent A.
Traber, Peter G.
HEPATOLOGY, 2014, 60 : 225A - 226A
[36] EFFECT OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 3 TRIAL
Navarro-Compan, V.
Wei, J. C. C.
Van den Bosch, F.
Magrey, M.
Wang, L.
Fleishaker, D.
Cappelleri, J. C.
Wang, C.
Wu, J.
Dina, O.
Fallon, L.
Strand, V.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 704 - 704
[37] Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial
Lachmann, Helen
Lauwerys, Bernard
Miettunen, Paivi
Kallinich, Tilmann
Jansson, Annette
Rosner, Itzhak
Manna, Raffaele
Murias, Saramaria
Savic, Sinisa
Smeets, Serge
De Benedetti, Fabrizio
Simon, Anna
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[38] Patient-reported outcomes with abrocitinib treatment in patients with moderate to severe atopic dermatitis: Results from a randomized, phase 3 clinical trial
Silverberg, Jonathan I.
Cohen, Arnon D.
Stander, Sonja
Feeney, Claire
Valdez, Hernan
Biswas, Pinaki
Cameron, Michael C.
DiBonaventura, Marco
Gerber, Robert A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB35 - AB35
[39] OBETICHOLIC ACID IMPROVES EXPERIMENTAL NON-INVASIVE MARKERS OF NON-ALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS; RESULTS OF A SECONDARY ANALYSIS FROM THE MONTH-18 INTERIM ANALYSIS OF THE REGENERATE STUDY
Boursier, Jerome
Loomba, Rohit
Anstee, Quentin M.
Harrison, Stephen
Sanyal, Arun J.
Rinella, Mary E.
Younossi, Zobair M.
Goodman, Zachary
Bedossa, Pierre
Fournier, Celine
Stenkilsson, Michael B.
Shringarpure, Reshma
Zaru, Luna
Venugopal, Aditya
MacConell, Leigh
Ratziu, Vlad
GASTROENTEROLOGY, 2020, 158 (06) : S1270 - S1271
[40] OBETICHOLIC ACID IMPROVES EXPERIMENTAL NON-INVASIVE MARKERS OF NON-ALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS: RESULTS OF A SECONDARY ANALYSIS FROM THE MONTH-18 INTERIM ANALYSIS OF THE REGENERATE STUDY
Digpal, Kuldip
Anstee, Quentin
GUT, 2020, 69 : A16 - A17

← 1 2 3 4 5 →